{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006916","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.115580+00:00","generated_at":"2026-06-02T18:30:49.190861+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"uniQure Q1 net loss narrows to $65.6M; cash $555.7M; advancing AMT-130 regulatory path","bullets":["Net loss $65.6M ($1.36/sh) vs $77.2M ($1.63) in Q1 2023; revenue $8.5M vs $5.3M.","Cash $555.7M (down from $617.9M Dec 2023); expects to fund operations into Q2 2027.","On track for FDA interaction for AMT-130 in Q2 2024; clinical update mid-2024 with up to 3-year data on 29 patients.","New Phase I/II trials: Fabry disease (AMT-191) enrollment begins Q2 2024; SOD1-ALS and MTLE expected Q3 2024.","Comprehensive operational review to reduce expenses underway, completion expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006916","json":"https://secwatch.observer/filing/0001558370-24-006916.json","markdown":"https://secwatch.observer/filing/0001558370-24-006916.md","text":"https://secwatch.observer/filing/0001558370-24-006916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/0001558370-24-006916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/qure-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:30:49.190861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9bc589c99850cd713738514246ee3dd5b0eb7818","claim":"uniQure N.V. reported the quarter ended March 31, 2024 results: revenue $8.5 million.","evidence_excerpt":"Revenue for the three months ended March 31, 2024 was $8.5 million, compared to $5.3 million in the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000155837024006916/0001558370-24-006916-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$8.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}